Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004026 · ClinicalTrials.gov registry record · Phase 2
CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy
A Phase 2 study, sponsored by CTI BioPharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00004026: Clinical Trial Phase 2 study, sponsored by CTI BioPharma.
NCT00004026 is a Phase 2 study that was terminated before completion, run by CTI BioPharma. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004026, a Phase 2 study, was terminated before completion, sponsored by CTI BioPharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. CT-2584 may stop the growth of prostate cancer by stopping blood flow to the tumor. PURPOSE: Randomized phase II trial to study the effectiveness of CT-2584 in treating patients who have metastatic prostate cancer that has not responded to previous therapy.
Interventions
- DRUG chemotherapy
- DRUG CT-2584
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 1998-12 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
Why NCT00004026 stopped before completion
NCT00004026 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 2 interventions - of which chemotherapy is the first listed.
NCT00004026 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004026 about?
NCT00004026 is a clinical study titled "CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. CT-2584 may stop the growth of prostate cancer by stopping blood flow to the tumor. PURPOSE: Randomized phase II trial to study the effectiveness of CT-2584 in treating patients w...
What is the current status of trial NCT00004026?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 1998-12. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00004026?
The interventions under investigation include: chemotherapy (DRUG), CT-2584 (DRUG).
Who is sponsoring clinical trial NCT00004026?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00004026's enrollment target sits among peer trials
80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia